Pancreatic Cancer Research

Clinical trialPhase 2Unknown

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer

A Single-arm, Multicenter, Phase Ⅱ Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer Who Have Received at Least One Line of Therapy

Outcome
Outcome unknown
Phase
Phase 2
Status
Unknown
Study type
Interventional
Start
6 December 2022
Listed end
30 June 2025
Enrollment
53 participants
Sites
1
Primary outcomes
Overall response rate (ORR) by Independent Review Committee (IRC)
Sponsor type
Industry
Results posted
No
Last update
22 March 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This trial is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) in patients with pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

Simon two-stage design will be adopted in this study. In the first stage, 24 patients will be enrolled, if at least 2 of them get response (CR or PR), the second stage of the study will be conducted, and 29 additional patients will be enrolled. If there is only one or no patients get response (CR or PR) in the first stage, the study will be early terminated.